SEARCH OUR PAGES

Headlines

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation; The peer-reviewed publication identifies a new T-cell exclusion mechanism attributed to CD47-SIRPα signaling.

A clinical-stage biotechnology company in immunotherapy

focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.

4

Products in clinical-stage status

3

Partnerships with international pharma companies

50

High-level collaborators

OSE Immunotherapeutics,
a clinical-stage biotechnology company

focused on developing and partnering therapies to control the immune system
for immuno-oncology and autoimmmune diseases.

Collaborations and partnerships

A fundamental element of both long-term strategy and day-to-day operations

  • Scientific and Technological
    Platforms

    Neoepitopes,
    agonist or antagonist monoclonal antibodies

    +
  • Immuno-oncology

    T-cell activation through neoepitopes
    Transforming tumor microenvironment
    suppressive cells into effector cells

    +
  • Autoimmune Diseases

    Down regulating T effector cells to decrease immunological reactivity

    Up regulating regulatory
    T-cells to develop immune tolerance

    +
  • Partnerships

    Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

    +

Our latest news

OSE Immunotherapeutics Announces Publication Supporting…

DISCOVER +

OSE Immunotherapeutics Receives European Patent…

DISCOVER +

OSE Immunotherapeutics Presents Positive Step-1…

DISCOVER +

OSE Immunotherapeutics Reports First Half…

DISCOVER +

To receive OSE Immunotherapeutics’ latest news